Stratifying SLN incidence in intermediate thickness melanoma patients

James M. Chang, Heidi E. Kosiorek, Amylou C. Dueck, Stanley P.L. Leong, John T. Vetto, Richard L. White, Eli Avisar, Vernon K. Sondak, Jane L. Messina, Jonathan S. Zager, Carlos Garberoglio, Mohammed Kashani-Sabet, Barbara A. Pockaj

    Research output: Contribution to journalArticlepeer-review

    16 Scopus citations


    Background: Guidelines for melanoma recommend sentinel lymph node biopsy (SLNB) in patients with melanomas ≥1 mm thickness. Recent single institution studies have found tumors <1.5 mm a low-risk group for positive SLNB. Methods: A retrospective review of the Sentinel Lymph Node Working Group multicenter database identified patients with intermediate thickness melanoma (1.01–4.00 mm) who had SLNB, and assessed predictors for positive SLNB. Results: 3460 patients were analyzed, 584 (17%) had a positive SLNB. Univariate factors associated with a positive SLNB included age <60 (p <.001), tumor on the trunk/lower extremity (p <.001), Breslow depth ≥2 mm (p <.001), ulceration (p <.001), mitotic rate ≥1/mm2 (p =.01), and microsatellitosis (p <.001). Multivariate analysis revealed age, location, and Breslow depth as significant predictors. Patients ≥75 with lesions 1.01–1.49 mm on the head/neck/upper extremity and 1.5–1.99 mm without high-risk features had <5% risk of SLN positivity. Conclusions: Intermediate thickness melanoma has significant heterogeneity of SLNB positivity. Low-risk subgroups can be found among older patients in the absence of high-risk features.

    Original languageEnglish (US)
    Pages (from-to)699-706
    Number of pages8
    JournalAmerican journal of surgery
    Issue number4
    StatePublished - Apr 2018

    ASJC Scopus subject areas

    • Surgery


    Dive into the research topics of 'Stratifying SLN incidence in intermediate thickness melanoma patients'. Together they form a unique fingerprint.

    Cite this